EPCAM and non-small cell lung carcinoma: However, the variation patterns of EpCAM+ CTCs and CTECs in both ascending and descending cohorts of NSCLC patients treated with anti‐angiogenic combination regimen consistently matched the total CTCs’ and CTECs’ fluctuation from t0 to t2.